MX2016004063A - Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. - Google Patents
Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.Info
- Publication number
- MX2016004063A MX2016004063A MX2016004063A MX2016004063A MX2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A
- Authority
- MX
- Mexico
- Prior art keywords
- pcv2
- pcv2b
- infection
- subtype
- prevention
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 241001673669 Porcine circovirus 2 Species 0.000 abstract 7
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 abstract 3
- 101710113540 ORF2 protein Proteins 0.000 abstract 3
- 101710090523 Putative movement protein Proteins 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulgan métodos de vacunación para controlar la infección por PCV2 con diferentes subtipos de PCV2. Específicamente, una proteína PCV2 ORF2 subtipo b (PCV2b) o las composiciones inmunogénicas que comprenden una proteína PCV2b ORE2 se usan en un método para el tratamiento o la prevención de una infección por PCV2 del mismo subtipo PCV2b y/o un subtipo diferente; la reducción, la prevención o el tratamiento de los signos clínicos causados por la infección por PCV2 del mismo subtipo PCV2b o un subtipo diferente; y/o la prevención o el tratamiento de una enfermedad causada por una infección por PCV2 del mismo subtipo PCV2b y/o un subtipo diferente. La presente invención se refiere en particular a las proteínas PCV2 ORF2 subtipo b (PCV2b) caracterizadas porque contienen por lo menos una mutación del bucle BC de modo tal que la proteína expresada se expresa preferentemente en una cantidad más alta comparado con una proteína PCV2 ORF2 que no contiene la mutación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361885871P | 2013-10-02 | 2013-10-02 | |
PCT/US2014/058793 WO2015051099A1 (en) | 2013-10-02 | 2014-10-02 | Pcv2 orf2 protein variant and virus like particles composed thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016004063A true MX2016004063A (es) | 2016-06-06 |
Family
ID=51795768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004063A MX2016004063A (es) | 2013-10-02 | 2014-10-02 | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. |
Country Status (12)
Country | Link |
---|---|
US (5) | US9505808B2 (es) |
EP (1) | EP3052516B1 (es) |
JP (1) | JP6778104B2 (es) |
KR (2) | KR102409183B1 (es) |
CN (1) | CN105658660A (es) |
AU (1) | AU2014329524B2 (es) |
CA (1) | CA2924228C (es) |
DK (1) | DK3052516T3 (es) |
EA (1) | EA035265B1 (es) |
ES (1) | ES2778425T3 (es) |
MX (1) | MX2016004063A (es) |
WO (1) | WO2015051099A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
MX2008008311A (es) | 2005-12-29 | 2009-03-04 | Boehringer Ingelheim Vetmed | Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos. |
EP1968630B1 (en) | 2005-12-29 | 2018-01-24 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent pcv2 immunogenic compositions |
WO2008073464A2 (en) | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
EP2242511A4 (en) | 2008-01-23 | 2012-10-24 | Boehringer Ingelheim Vetmed | IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS |
AU2014329524B2 (en) * | 2013-10-02 | 2019-01-17 | Boehringer Ingelheim Animal Health USA Inc. | PCV2 ORF2 protein variant and virus like particles composed thereof |
WO2016160761A2 (en) * | 2015-03-30 | 2016-10-06 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 carrier platform |
EP3294876A1 (en) * | 2015-05-14 | 2018-03-21 | Merial, Inc. | Method for porcine circovirus production and pcv2 vaccines |
CN104984335A (zh) * | 2015-07-14 | 2015-10-21 | 浙江诺倍威生物技术有限公司 | 猪圆环病毒双亚型orf2共表达载体构建及疫苗制备 |
AU2017257302A1 (en) * | 2016-03-07 | 2018-09-27 | Virginia Tech Intellectual Properties, Inc. | Chimeric porcine circovirus type 2 (PCV2) vaccines |
US10431889B2 (en) * | 2016-04-22 | 2019-10-01 | The Charles Stark Draper Laboratory, Inc. | Low-loss compact transmit impedance matching tuning technique |
CN106399138B (zh) * | 2016-09-07 | 2019-11-12 | 复旦大学 | 猪圆环病毒ii型口服病毒样颗粒疫苗及其制备方法和应用 |
CN106399350B (zh) * | 2016-09-07 | 2020-02-21 | 复旦大学 | 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法 |
WO2018083154A1 (en) * | 2016-11-03 | 2018-05-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus |
CN106834242B (zh) * | 2017-03-02 | 2021-02-23 | 扬州大学 | 嵌合型猪圆环病毒活疫苗c1-233株及其构建方法 |
CN106834241B (zh) * | 2017-03-02 | 2021-01-19 | 扬州大学 | 嵌合型猪圆环病毒活疫苗c1-402株及其构建方法 |
CN107245477B (zh) * | 2017-06-06 | 2020-06-30 | 广东海大畜牧兽医研究院有限公司 | 一种猪圆环病毒2型病毒样颗粒的制备方法及通过该方法获得的病毒样颗粒 |
CN111212847B (zh) | 2017-10-17 | 2024-01-30 | 英特维特国际股份有限公司 | PCV2b ORF2蛋白在昆虫细胞中的重组表达 |
CN108484725A (zh) * | 2018-03-16 | 2018-09-04 | 广东海大畜牧兽医研究院有限公司 | 一种区分检测pcv2野毒抗体与疫苗抗体的多肽及其在elisa检测试剂盒中的应用 |
CN110358742B (zh) * | 2019-07-05 | 2020-12-22 | 武汉科前生物股份有限公司 | 猪圆环病毒2b型和2d型的二价亚单位疫苗及其制备方法 |
CN111415356B (zh) * | 2020-03-17 | 2020-12-29 | 推想医疗科技股份有限公司 | 肺炎征象的分割方法、装置、介质及电子设备 |
CN112010949B (zh) * | 2020-08-03 | 2021-07-27 | 山东绿都生物科技有限公司 | 一种重组pcv2病毒样颗粒蜂胶疫苗及其制备方法 |
CN114250259A (zh) * | 2020-09-21 | 2022-03-29 | 成都天邦生物制品有限公司 | 一种猪圆环2型病毒Cap蛋白病毒样颗粒的发酵培养基 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
ES2052685T3 (es) | 1987-03-17 | 1994-07-16 | Akzo Nv | Metodo para producir un adyuvante libre. |
US5069901A (en) | 1988-02-03 | 1991-12-03 | Jones Elaine V | Preparation of a recombinant subunit vaccine against pseudorabies infection |
AU638970B2 (en) | 1989-01-23 | 1993-07-15 | Auspharm International Limited | Vaccine composition |
US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
US5202430A (en) | 1990-01-16 | 1993-04-13 | University Of Tennessee | Transmissible gastroenteritis virus genes |
ATE160699T1 (de) | 1990-05-29 | 1997-12-15 | American Cyanamid Co | Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung |
US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
GB9023111D0 (en) | 1990-10-24 | 1990-12-05 | Wellcome Found | Expression system |
WO1992007934A1 (en) | 1990-11-01 | 1992-05-14 | Iowa State University Research Foundation, Inc. | Bacterial attenuation method and vaccine |
US6042830A (en) | 1992-08-05 | 2000-03-28 | Boehringer Ingelheim Vetmedica, Inc. | Viral agent associated with mystery swine disease |
CA2076744C (en) | 1991-08-26 | 2000-06-27 | Danny W. Chladek | Viral agent associated with mystery swine disease |
US5580557A (en) | 1991-10-09 | 1996-12-03 | Iowa State University Research Foundation, Inc. | Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
CA2189979C (en) | 1994-05-10 | 2011-04-19 | Hsien-Jue Chu | Improved modified live brsv vaccine |
US5885823A (en) | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
US5888532A (en) | 1996-08-16 | 1999-03-30 | Pritsos; Chris A. | Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives |
EP0835930B1 (en) | 1996-10-09 | 2001-01-31 | Akzo Nobel N.V. | European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV) |
US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
FR2781159B1 (fr) | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
US20060029617A1 (en) | 1997-10-03 | 2006-02-09 | Charreyre Catherine E | Porcine circovirus and Helicobacter combination vaccines and methods of use |
US7211379B2 (en) | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
US20040062775A1 (en) | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
KR100879650B1 (ko) | 1997-12-11 | 2009-01-20 | 유니버시티 오브 사스카췌완 | 돼지로부터의 이유후 다기관계작용성 소모 증후군 바이러스 |
EP1064024A4 (en) | 1998-03-13 | 2005-04-06 | Univ Georgia Res Found | VACCINES AGAINST CIRCOVIRUS INFECTIONS |
EP0953574A1 (en) * | 1998-04-30 | 1999-11-03 | Innogenetics N.V. | Immunodiagnostic reagent for the detection of Maedi-Visna virus and CAEV infection |
US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
US6472193B1 (en) | 1998-11-19 | 2002-10-29 | Azwell Inc. | Recombinant lysophosphatidic acid phosphatase |
FR2789695B1 (fr) | 1999-02-11 | 2003-03-07 | Merial Sas | Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs |
US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
WO2001017556A1 (fr) | 1999-09-07 | 2001-03-15 | Shionogi & Co., Ltd. | Préparations vaccinales administrables par les muqueuses |
US6656478B1 (en) | 1999-11-12 | 2003-12-02 | Samuel D. Charles | Cross-protective salmonella vaccines |
WO2001045735A2 (en) | 1999-12-21 | 2001-06-28 | Merial | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen |
CA2410229A1 (en) | 2000-06-15 | 2001-12-20 | Purdue Research Foundation | Vaccine for congenital tremors in pigs |
US6808900B2 (en) | 2000-06-15 | 2004-10-26 | Manitoba, University Of | Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
JP2002247979A (ja) | 2001-02-23 | 2002-09-03 | Nippon Biologicals Inc | マレック病ワクチンおよびその製造方法 |
MY146518A (en) | 2001-03-27 | 2012-08-15 | Univ Saskatchewan | Methods to culture circovirus. |
US20030096377A1 (en) | 2001-06-28 | 2003-05-22 | Virginia Tech Intellectual Properties, Inc. | Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2 |
PL209773B1 (pl) | 2001-07-02 | 2011-10-31 | Pfizer Prod Inc | Zastosowanie bakteryny Mycoplasma hyopneumoniae do wytwarzania szczepionki |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US7279166B2 (en) | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US7276353B2 (en) | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US6841364B2 (en) | 2002-01-22 | 2005-01-11 | Protatek International, Inc. | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof |
WO2003068163A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
US20030199581A1 (en) | 2002-03-13 | 2003-10-23 | Seligson Allen L. | Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses |
US20030215455A1 (en) | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
AU2002951692A0 (en) | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
WO2004069184A2 (en) | 2003-02-03 | 2004-08-19 | Cerebus Biologicals, Inc. | Methods for treating, preventing and detecting helicobacter infection |
US7563449B2 (en) | 2003-04-21 | 2009-07-21 | Pfizer Inc, | Methods for reducing cattle reproductive diseases |
CN1458167A (zh) | 2003-06-02 | 2003-11-26 | 中国农业科学院哈尔滨兽医研究所 | 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用 |
US7335361B2 (en) | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
EP1651265B1 (en) | 2003-07-24 | 2008-04-23 | Merial Limited | Vaccine formulations comprising an oil-in-water emulsion |
JP2006528882A (ja) | 2003-07-25 | 2006-12-28 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | 欧州起源のローソニア・イントラセルラリス並びにそのワクチン、診断薬及び使用方法 |
FR2861731B1 (fr) | 2003-10-30 | 2006-02-24 | Centre Nat Rech Scient | Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations |
CN1942204A (zh) | 2004-04-26 | 2007-04-04 | 株式会社中央疫苗研究所 | 用于猪呼吸病的灭活混合疫苗及其制备方法 |
CN1579553A (zh) | 2004-05-18 | 2005-02-16 | 浙江大学 | Ii型猪圆环病毒核酸疫苗的制备方法及其应用 |
US20060286124A1 (en) | 2004-06-30 | 2006-12-21 | Id Biomedical Corporation Of Quebec | Vaccine compositions and methods of treating coronavirus infection |
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
WO2006074986A2 (en) | 2005-01-13 | 2006-07-20 | Boehringer Ingelheim Vetmedica Gmbh | Prrs vaccines |
US7300785B2 (en) | 2005-02-03 | 2007-11-27 | Universiteit Ghent | Culturing circular ssDNA viruses for the production of vaccines |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
MX2007012786A (es) | 2005-04-13 | 2008-01-11 | Merial Ltd | Ensayo para produccion de circovirus porcino. |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
CA2620727C (en) | 2005-09-09 | 2015-06-16 | Intervet International B.V. | Porcine circovirus type 2 vaccine |
EP1968630B1 (en) | 2005-12-29 | 2018-01-24 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent pcv2 immunogenic compositions |
MX2008008311A (es) | 2005-12-29 | 2009-03-04 | Boehringer Ingelheim Vetmed | Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos. |
US20100136060A1 (en) | 2006-11-22 | 2010-06-03 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing porcine circovirus-associated disease outbreaks |
WO2008073464A2 (en) | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
CN107412761A (zh) * | 2006-12-15 | 2017-12-01 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 以pcv2抗原治疗猪 |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
GB0712160D0 (en) | 2007-06-22 | 2007-08-01 | Univ Ghent | Methods and compositions in the treatment of procine circoviral infection |
US20090017064A1 (en) | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
WO2009085912A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth | Methods and compositions for immunizing pigs against porcine circovirus |
EP2242511A4 (en) | 2008-01-23 | 2012-10-24 | Boehringer Ingelheim Vetmed | IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS |
EP2254595A4 (en) | 2008-02-15 | 2012-12-05 | Boehringer Ingelheim Vetmed | METHODS AND COMPOSITIONS FOR REDUCING THE IMPACT OF ENTERIC DISEASES |
US8444989B1 (en) | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
EP3639852A1 (en) | 2010-03-16 | 2020-04-22 | Virginia Tech Intellectual Properties, Inc. | Live attenuated chimeric porcine circovirus vaccine |
CN102859875B (zh) | 2010-04-22 | 2016-10-05 | 皇家飞利浦电子股份有限公司 | 皮肤接触检测器 |
CA2804604C (en) | 2010-07-08 | 2023-10-03 | United Biomedical, Inc. | Designer peptide-based pcv2 vaccine |
US9580474B2 (en) | 2010-09-08 | 2017-02-28 | The Johns Hopkins University | Polyionic papilloma virus-like particle (VLP) vaccines |
EP2564869A1 (en) | 2011-09-02 | 2013-03-06 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
CN103122352B (zh) | 2012-09-27 | 2015-02-11 | 华中农业大学 | 一种猪圆环病毒2型重组杆状病毒及制备方法和应用 |
ES2734374T3 (es) * | 2013-03-01 | 2019-12-05 | Boehringer Ingelheim Animal Health Usa Inc | Cuantificación de composiciones de vacuna |
US20140322267A1 (en) | 2013-04-30 | 2014-10-30 | Boehringer Ingelheim Vetmedica, Inc. | Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection |
AU2014329524B2 (en) * | 2013-10-02 | 2019-01-17 | Boehringer Ingelheim Animal Health USA Inc. | PCV2 ORF2 protein variant and virus like particles composed thereof |
ES2954961T3 (es) | 2014-05-07 | 2023-11-27 | Boehringer Ingelheim Int | Unidad, nebulizador y método |
WO2016160761A2 (en) | 2015-03-30 | 2016-10-06 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 carrier platform |
-
2014
- 2014-10-02 AU AU2014329524A patent/AU2014329524B2/en active Active
- 2014-10-02 US US14/504,839 patent/US9505808B2/en active Active
- 2014-10-02 CA CA2924228A patent/CA2924228C/en active Active
- 2014-10-02 JP JP2016519871A patent/JP6778104B2/ja active Active
- 2014-10-02 KR KR1020167011660A patent/KR102409183B1/ko active IP Right Grant
- 2014-10-02 CN CN201480054488.4A patent/CN105658660A/zh active Pending
- 2014-10-02 MX MX2016004063A patent/MX2016004063A/es active IP Right Grant
- 2014-10-02 DK DK14789683.1T patent/DK3052516T3/da active
- 2014-10-02 EA EA201600305A patent/EA035265B1/ru not_active IP Right Cessation
- 2014-10-02 KR KR1020227019654A patent/KR20220083861A/ko not_active Application Discontinuation
- 2014-10-02 ES ES14789683T patent/ES2778425T3/es active Active
- 2014-10-02 WO PCT/US2014/058793 patent/WO2015051099A1/en active Application Filing
- 2014-10-02 EP EP14789683.1A patent/EP3052516B1/en active Active
-
2016
- 2016-10-17 US US15/295,053 patent/US10131696B2/en active Active
-
2018
- 2018-10-08 US US16/154,294 patent/US10961281B2/en active Active
-
2021
- 2021-03-29 US US17/215,636 patent/US11858963B2/en active Active
-
2023
- 2023-11-21 US US18/516,237 patent/US20240076321A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016534034A (ja) | 2016-11-04 |
CA2924228A1 (en) | 2015-04-09 |
AU2014329524A1 (en) | 2016-03-17 |
KR20160058958A (ko) | 2016-05-25 |
KR102409183B1 (ko) | 2022-06-15 |
EA201600305A1 (ru) | 2016-09-30 |
US10961281B2 (en) | 2021-03-30 |
JP6778104B2 (ja) | 2020-10-28 |
CA2924228C (en) | 2024-01-16 |
WO2015051099A1 (en) | 2015-04-09 |
ES2778425T3 (es) | 2020-08-10 |
US9505808B2 (en) | 2016-11-29 |
DK3052516T3 (da) | 2020-03-23 |
US20240076321A1 (en) | 2024-03-07 |
EP3052516A1 (en) | 2016-08-10 |
EA035265B1 (ru) | 2020-05-21 |
CN105658660A (zh) | 2016-06-08 |
US10131696B2 (en) | 2018-11-20 |
US20210221852A1 (en) | 2021-07-22 |
US11858963B2 (en) | 2024-01-02 |
KR20220083861A (ko) | 2022-06-20 |
US20150093404A1 (en) | 2015-04-02 |
US20190023747A1 (en) | 2019-01-24 |
EP3052516B1 (en) | 2020-01-01 |
AU2014329524B2 (en) | 2019-01-17 |
US20170029471A1 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016004063A (es) | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. | |
MX2018014573A (es) | Vacuna contra el virus del zika. | |
EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
MX354750B (es) | PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA. | |
EA201590890A1 (ru) | Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
MX2014004814A (es) | Compuestos y metodos para mejorar las respuestas inmunes innatas. | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
PH12015501378A1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
PH12017500450A1 (en) | Flavivirus virus like particle | |
WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
PH12015501721A1 (en) | Porcine parvovirus 5b, methods of use and vaccine | |
WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
WO2014140166A3 (en) | Vaccine | |
MX2014014521A (es) | Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos. | |
EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
PH12014501688A1 (en) | Influenza c virus and vaccine | |
MX2014001158A (es) | Virus recombinantes de influenza porcina y usos del mismo. | |
EA201390452A1 (ru) | Вакцина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. |
|
FG | Grant or registration |